The Efficacy and Safety of Donafenib Combined With Anti-PD-1 Antibody for Neoadjuvant Therapy in Locally Advanced Thyroid Cancer: a Phase II Study
Latest Information Update: 29 Jan 2025
Price :
$35 *
At a glance
- Drugs Donafenib (Primary) ; Sintilimab (Primary)
- Indications Thyroid cancer
- Focus Therapeutic Use
- 29 Jan 2025 New trial record